Coming of age: taking the next steps with non-viral gene delivery

Abstract

<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Stanton headshot copy.png" data-image="1"></div><div class="author-det"> <b>Matt Stanton</b> is Chief Scientific Officer at Generation Bio where he oversees core platform research, production and process and analytical research. Prior to joining Generation Bio, Dr. Stanton served as Vice President, Head of Chemistry and Immunology at Moderna where he led nucleotide and delivery chemistry as well as basic platform immunology in support of mRNA therapeutics discovery. Previously, Dr. Stanton was Director and head of RNA medicinal chemistry at Merck, spending 16 years in roles of increasing leadership, including small molecule program leadership and head of chemistry capabilities enhancement. He was involved in numerous therapeutic areas including oncology, cardiovascular, neuroscience and infectious disease that spanned a range of modalities including small molecules, siRNA and peptide conjugates. Dr. Stanton graduated from Virginia Tech with a B.S. in chemistry and earned his Ph.D. in chemistry from the University of North Carolina at Chapel Hill with a focus on physical organic chemistry and natural product synthesis. </div></div></div>